Beta Bionics faces securities fraud class action
Beta Bionics faces a securities class action tied to allegations over disclosures about its iLet automated insulin delivery system and FDA concerns. The suit seeks to represent investors who bought shares between July 30, 2025 and Feb. 24, 2026.